Management of Brucella endocarditis: results of the Gulhane study
| Autor: | Saim Dayan, Hakan Erdem, Özcan Deveci, Ayşe Erbay, Esra Kazak, Sema Alp-Cavus, Ali Rıza Erbay, Elif Doyuk-Kartal, İbrahim Koruk, Rahmet Guner, Umit Savasci, Oğuz Reşat Sipahi, Behice Kurtaran, Yasemin Tezer-Tekce, Aysun Yalci, Serap Gencer, Mehmet Parlak, Derya Ozturk Engin, Necla Tulek, Mucahit Yemisen, Filiz Pehlivanoglu, Asuman Inan, Suda Tekin Koruk, Oral Oncul, Gokhan Guzel, Asim Ulcay, Nebahat Dikici |
|---|---|
| Přispěvatelé: | Çukurova Üniversitesi, [Koruk, Suda Tekin] Harran Univ, Sch Med, Dept Infect Dis & Clin Microbiol IDCM, Sanliurfa, Turkey -- [Erdem, Hakan -- Ulcay, Asim] Kasimpasa Hosp, Dept IDCM, Istanbul, Turkey -- [Koruk, Ibrahim] Harran Univ, Sch Med, Dept Publ Hlth, Sanliurfa, Turkey -- [Erbay, Ayse] Bozok Univ, Sch Med, Dept IDCM, Yozgat, Turkey -- [Tezer-Tekce, Yasemin] Turkiye Yuksek Ihtisas Training & Res Hosp, Dept IDCM, Ankara, Turkey -- [Erbay, Ali Riza] Bozok Univ, Sch Med, Dept Cardiol, Yozgat, Turkey -- [Dayan, Saim -- Deveci, Ozcan] Dicle Univ, Sch Med, Dept IDCM, Diyarbakir, Turkey -- [Inan, Asuman -- Engin, Derya Ozturk] Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey -- [Guner, Rahmet] Ataturk Training & Res Hosp, Dept IDCM, Ankara, Turkey -- [Dikici, Nebahat] Selcuk Univ, Fac Selcuklu Med, Konya, Turkey -- [Doyuk-Kartal, Elif] Osmangazi Univ, Sch Med, Dept IDCM, Eskisehir, Turkey -- [Kurtaran, Behice] Cukurova Univ, Sch Med, Dept IDCM, Adana, Turkey -- [Pehlivanoglu, Filiz] Haseki Training & Res Hosp, Dept IDCM, Istanbul, Turkey -- [Sipahi, Oguz Resat] Ege Univ, Sch Med, Dept IDCM, Izmir, Turkey -- [Yalci, Aysun] Ankara Univ, Sch Med, Dept IDCM, TR-06100 Ankara, Turkey -- [Yemisen, Mucahit] Istanbul Univ, Cerrahpasa Med Sch, Dept IDCM, Istanbul, Turkey -- [Alp-Cavus, Sema] Dokuz Eylul Univ, Sch Med, Dept IDCM, Izmir, Turkey -- [Gencer, Serap] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept IDCM, Istanbul, Turkey -- [Guzel, Gokhan] Cumhuriyet Univ, Sch Med, Dept IDCM, Sivas, Turkey -- [Oncul, Oral] Gulhane Haydarpasa Hosp, Dept IDCM, Istanbul, Turkey -- [Parlak, Mehmet] Ataturk Univ, Sch Med, Dept IDCM, Erzurum, Turkey -- [Kazak, Esra] Uludag Sch Med, Dept IDCM, Bursa, Turkey -- [Tulek, Necla] Ankara Numune Training & Res Hosp, Dept IDCM, Ankara, Turkey -- [Savasci, Umit] Mil Hosp, IDCM Serv, Sarikamis, Turkey, Kurtaran, Behice -- 0000-0002-2081-4664, GENCER, SERAP -- 0000-0002-3217-6305, Gencer, Serap -- 0000-0002-3217-6305, Gozel, Mustafa Gokhan -- 0000-0001-5187-7388, Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Kazak, Esra, AAG-8459-2021 |
| Rok vydání: | 2012 |
| Předmět: |
Congestive heart failure
Male Turkey Bacterial endocarditis Antibiotics Pericardial effusion Leukocyte Count Ciprofloxacin Diagnosis Pharmacology (medical) Gentamicin Heart valve prosthesis Priority journal Aged 80 and over Endocarditis Ceftriaxone Heart General Medicine Middle Aged Bacterial-endocarditis Risk-factors Infectious Diseases Treatment Outcome Doxycycline Aortic Valve Streptomycin Mitral Valve Drug Therapy Combination Female Tricuspid Valve Aorta valve Human medicine.drug Microbiology (medical) Adult medicine.medical_specialty medicine.drug_class Brucella endocarditis Major clinical study Microbiology Article Brucellosis Young Adult Pharmacotherapy medicine Adults Agglutination Tests Zoonosis Humans Mortality Rifampicin Aged Retrospective Studies Pharmacology & pharmacy business.industry Retrospective cohort study Endocarditis Bacterial medicine.disease Valvular heart disease Brucella Cotrimoxazole Heart surgery Surgery Aminoglycosides Therapy Infective endocarditis Complication business |
| Zdroj: | International journal of antimicrobial agents. 40(2) |
| ISSN: | 1872-7913 2272-7531 |
| Popis: | WOS: 000306663800009 PubMed ID: 22727531 Brucella endocarditis (BE) is a rare but life-threatening complication of human brucellosis. The aim of this study was to investigate the course of BE along with the therapeutic interrelations. A total of 53 patients with BE hospitalised in 19 health institutions between 2006 and 2011 were included in the Gulhane study. Diagnosis of brucellosis was established by either isolation of Brucella sp. or the presence of antibodies, and the definition of endocarditis was made according to Duke's criteria. There were four treatment groups: ceftriaxone combined with oral antibiotics (Group 1); aminoglycosides combined with oral antibiotics (Group 2); oral antibiotic combinations (Group 3); and aminoglycoside plus ceftriaxone combined with an oral antibiotic (Group 4). Involvement rates of the aortic, mitral and tricuspid valves were 49.1%, 43.4% and 5.7%, respectively. Thirty-two patients (60.4%) had an underlying cardiac valvular problem, including previous prosthetic valve replacement (n = 18). Medical treatment was provided to 32 patients (60.4%), whilst concordant medical and surgical approaches were provided to 21 patients (39.6%). Mortality in Group 1 was 15% (3/20), whilst in Group 2 it was 5.3% (1/19). In Group 3, 25.0% (3/12) of the cases died, whereas none of the cases in Group 4 died. In conclusion, mortality increased 47-fold with pericardial effusion and 25-fold due to congestive heart failure that developed after BE. Although mortality was lower in the aminoglycoside-containing arm (Groups 2 and 4), statistical analysis could not be performed owing to the small number of patients. (C) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect